Sanara MedTech (NASDAQ:SMTI – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.
Volatility and Risk
Sanara MedTech has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500. Comparatively, biote has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current ratings and price targets for Sanara MedTech and biote, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sanara MedTech | 2 | 0 | 2 | 0 | 2.00 |
| biote | 1 | 1 | 2 | 0 | 2.25 |
Profitability
This table compares Sanara MedTech and biote’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sanara MedTech | -31.23% | -3.19% | -0.56% |
| biote | 8.29% | -25.72% | 15.12% |
Insider & Institutional Ownership
8.1% of Sanara MedTech shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 42.0% of Sanara MedTech shares are owned by insiders. Comparatively, 32.4% of biote shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Sanara MedTech and biote”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sanara MedTech | $103.12 million | 2.02 | -$37.56 million | ($3.77) | -6.04 |
| biote | $192.22 million | 0.39 | $27.05 million | $0.44 | 4.58 |
biote has higher revenue and earnings than Sanara MedTech. Sanara MedTech is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Summary
biote beats Sanara MedTech on 9 of the 13 factors compared between the two stocks.
About Sanara MedTech
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
Receive News & Ratings for Sanara MedTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanara MedTech and related companies with MarketBeat.com's FREE daily email newsletter.
